SG Americas Securities
GEVA

SG Americas Securities’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

SG Americas Securities’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,168
Closed -$114K – 3021
2015
Q1 		$114K Sell
1,168
-4,726
-80% -$500K ﹤0.01% 2201
2014
Q4 		$547K Buy
5,894
+3,267
+124% +$258K ﹤0.01% 1588
2014
Q3 		$181K Buy
+2,627
New +$188K ﹤0.01% 2028
2014
Q2 		– Sell
-9,662
Closed -$802K – 2875
2014
Q1 		$802K Buy
+9,662
New +$893K ﹤0.01% 1231
2013
Q4 		– Sell
-3,030
Closed -$192K – 3339
2013
Q3 		$192K Buy
+3,030
New +$149K ﹤0.01% 2215

SG Americas Securities's GEVA Position: Q2 2015 in Review

SG Americas Securities sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,168 shares — an estimated $114K sold.

SG Americas Securities first reported a position in GEVA in Q3 2013 and held it in 5 quarters. The position peaked at $802K in Q1 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • SG Americas Securities reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • SG Americas Securities sold 1,168 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $114K.
  • SG Americas Securities first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 5 quarters.
  • SG Americas Securities's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $802K in Q1 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on SG Americas Securities's 13F filing for Q2 2015, filed 6 Aug 2015.